CA3129533A1 - Composes bicycliques substitues utilises en tant que modulateurs du recepteur farnesoide x - Google Patents

Composes bicycliques substitues utilises en tant que modulateurs du recepteur farnesoide x Download PDF

Info

Publication number
CA3129533A1
CA3129533A1 CA3129533A CA3129533A CA3129533A1 CA 3129533 A1 CA3129533 A1 CA 3129533A1 CA 3129533 A CA3129533 A CA 3129533A CA 3129533 A CA3129533 A CA 3129533A CA 3129533 A1 CA3129533 A1 CA 3129533A1
Authority
CA
Canada
Prior art keywords
oxadiazol
octan
methyl
bicyclo
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129533A
Other languages
English (en)
Inventor
Dean A. Wacker
Susheel Jethanand NARA
Srinivas CHERUKU
Kandhasamy SARKUNAM
Firoz Ali JAIPURI
Rishikesh Narayan
Subba Reddy BANDREDDY
Srinivas JOGI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA3129533A1 publication Critical patent/CA3129533A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (I) : ou un stéréoisomère, un tautomère, ou un de leurs sels ou solvates, où Q représente un alcényle en C2 à C6 ou un alcynyle en C2 à C6<sb /> <sb />, chacun étant substitué par zéro à 2 R1; et les autres variables étant telles que définies dans la description. Ces composés modulent l'activité du récepteur farnésoïde X (FXR), par exemple, en tant qu'agonistes. La présente invention concerne également des compositions pharmaceutiques comprenant ces composés et des méthodes de traitement d'une maladie, d'un trouble ou d'un état associé à un dérèglement de FXR, tels que la fibrose pathologique, le rejet de greffe, le cancer, l'ostéoporose et des troubles inflammatoires, à l'aide des composés et des compositions pharmaceutiques.
CA3129533A 2019-02-15 2020-02-14 Composes bicycliques substitues utilises en tant que modulateurs du recepteur farnesoide x Pending CA3129533A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806402P 2019-02-15 2019-02-15
US62/806,402 2019-02-15
PCT/US2020/018210 WO2020168148A1 (fr) 2019-02-15 2020-02-14 Composés bicycliques substitués utilisés en tant que modulateurs du récepteur farnésoïde x

Publications (1)

Publication Number Publication Date
CA3129533A1 true CA3129533A1 (fr) 2020-08-20

Family

ID=69811924

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129533A Pending CA3129533A1 (fr) 2019-02-15 2020-02-14 Composes bicycliques substitues utilises en tant que modulateurs du recepteur farnesoide x

Country Status (7)

Country Link
AU (1) AU2020221370A1 (fr)
BR (1) BR112021015963A2 (fr)
CA (1) CA3129533A1 (fr)
EA (1) EA202192263A1 (fr)
MX (1) MX2021009570A (fr)
SG (1) SG11202108796YA (fr)
WO (1) WO2020168148A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230060715A1 (en) 2020-01-15 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
US20240100125A1 (en) 2021-01-14 2024-03-28 Enyo Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
CN115340536B (zh) * 2021-05-13 2024-12-10 华东理工大学 含1,2,4-恶二唑的酰胺类化合物及其盐、制备方法和用途
EP4650002A1 (fr) * 2024-05-15 2025-11-19 Ludwig-Maximilians-Universität Modulateurs du récepteur nucléaire tlx (nr2e1)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480957A1 (fr) 2002-03-01 2004-12-01 Smithkline Beecham Corporation Activateurs de hppars
AU2003287178A1 (en) 2002-10-10 2004-05-04 Smithkline Beecham Corporation Chemical compounds
CA2603402C (fr) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions de 1,2,4-oxadiazole oralement actives pour un traitement de suppression de mutations non-sens
WO2008011130A2 (fr) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Composés amidés
EP2917203B1 (fr) 2012-11-02 2019-04-03 Dana-Farber Cancer Institute, Inc. Procédé d'identification d'inhibiteurs de myc
WO2015195880A1 (fr) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Dérivés d'imidazo-pyridazine en tant qu'inhibiteurs de la caséine kinase 1 delta/epsilon
WO2016039734A1 (fr) 2014-09-10 2016-03-17 Halliburton Energy Services, Inc. Perforateur avec système de retenue intégré
CN110637011B (zh) * 2017-03-15 2024-05-14 奥加诺沃公司 法尼醇x受体激动剂及其用途
AU2018236275B2 (en) * 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof

Also Published As

Publication number Publication date
EA202192263A1 (ru) 2022-01-27
AU2020221370A1 (en) 2021-10-07
WO2020168148A1 (fr) 2020-08-20
BR112021015963A2 (pt) 2021-10-05
MX2021009570A (es) 2021-09-08
SG11202108796YA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
US11713312B2 (en) Substituted bicyclic compounds as farnesoid X receptor modulators
AU2020221370A1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
EP4491622A2 (fr) Inhibiteurs de sarcomes cardiaques
CA3081424A1 (fr) Composes spirocycliques a utiliser en tant que modulateurs du recepteur farnesoide x
US12319676B2 (en) Substituted amide compounds useful as farnesoid X receptor modulators
US12227496B2 (en) Substituted bicyclic compounds as farnesoid X receptor modulators
US12030835B2 (en) Substituted amide compounds useful as farnesoid X receptor modulators
EA047337B1 (ru) Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора